WallStreetZenWallStreetZen

NASDAQ: SRRK
Scholar Rock Holding Corp Stock

$17.76+2.31 (+14.95%)
Updated Mar 28, 2024
Why Price Moved
SRRK Price
$17.76
Fair Value Price
$0.48
Market Cap
$1.38B
52 Week Low
$5.56
52 Week High
$21.17
P/E
-8.92x
P/B
6.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$165.79M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.38
Operating Cash Flow
-$145M
Beta
0.85
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SRRK Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SRRK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SRRK ($17.76) is overvalued by 3,597.19% relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SRRK ($17.76) is not significantly undervalued (3,597.19%) relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SRRK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SRRK due diligence checks available for Premium users.

Be the first to know about important SRRK news, forecast changes, insider trades & much more!

SRRK News

Valuation

SRRK fair value

Fair Value of SRRK stock based on Discounted Cash Flow (DCF)
Price
$17.76
Fair Value
$0.48
Overvalued by
3,597.19%
SRRK ($17.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SRRK ($17.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SRRK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SRRK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.92x
Industry
14.26x
Market
44.51x

SRRK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.14x
Industry
6.21x
SRRK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SRRK's financial health

Profit margin

Revenue
$0.0
Net Income
-$46.1M
Profit Margin
0%
SRRK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$311.0M
Liabilities
$85.8M
Debt to equity
0.38
SRRK's short-term assets ($288.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SRRK's short-term assets ($288.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SRRK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SRRK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$37.3M
Investing
-$25.1M
Financing
$96.5M
SRRK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SRRK vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SRRK$1.38B+14.95%-8.92x6.14x
SLNO$1.39B-0.12%-18.14x8.82x
KNSA$1.39B-1.30%98.65x3.17x
SYRE$1.37B+2.51%-0.77x7.45x
VIR$1.37B+0.30%-2.21x0.86x

Scholar Rock Holding Stock FAQ

What is Scholar Rock Holding's quote symbol?

(NASDAQ: SRRK) Scholar Rock Holding trades on the NASDAQ under the ticker symbol SRRK. Scholar Rock Holding stock quotes can also be displayed as NASDAQ: SRRK.

If you're new to stock investing, here's how to buy Scholar Rock Holding stock.

What is the 52 week high and low for Scholar Rock Holding (NASDAQ: SRRK)?

(NASDAQ: SRRK) Scholar Rock Holding's 52-week high was $21.17, and its 52-week low was $5.56. It is currently -16.11% from its 52-week high and 219.42% from its 52-week low.

How much is Scholar Rock Holding stock worth today?

(NASDAQ: SRRK) Scholar Rock Holding currently has 77,866,281 outstanding shares. With Scholar Rock Holding stock trading at $17.76 per share, the total value of Scholar Rock Holding stock (market capitalization) is $1.38B.

Scholar Rock Holding stock was originally listed at a price of $15.50 in May 24, 2018. If you had invested in Scholar Rock Holding stock at $15.50, your return over the last 5 years would have been 14.58%, for an annualized return of 2.76% (not including any dividends or dividend reinvestments).

How much is Scholar Rock Holding's stock price per share?

(NASDAQ: SRRK) Scholar Rock Holding stock price per share is $17.76 today (as of Mar 28, 2024).

What is Scholar Rock Holding's Market Cap?

(NASDAQ: SRRK) Scholar Rock Holding's market cap is $1.38B, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Scholar Rock Holding's market cap is calculated by multiplying SRRK's current stock price of $17.76 by SRRK's total outstanding shares of 77,866,281.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.